Company intelligence / Profile preview

SAGE Holding

Cambridge, Massachusetts, United Statessage.com ↗

Ownership: Private
Development stage: Other

Overview

Sage developed the first FDA-approved treatments specifically for postpartum depression—ZULRESSO (brexanolone, IV) and ZURZUVAE (zuranolone, oral). ZURZUVAE was co-developed with Biogen and approved in August 2023. The pipeline includes investigational drugs targeting cognitive disorders such as Huntington’s, Alzheimer’s, and Parkinson’s diseases. Revenue from ZURZUVAE reached $36.1 million in 2024.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeNeuroactive steroid
Industry: Biotech

Partnerships

Biogen (co-development/commercialization partner for zuranolone/ZURZUVAE until September 2024 termination)Shionogi & Co., Ltd. (holds rights to develop/commercialize zuranolone in Japan/Taiwan/South Korea)

Beyond the preview

Go deeper on SAGE Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAGE Holding.

Explore the full profile